101 terminated. 101 Phase 3, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 101 | Terminated 101 |
| Phase 2 | 21 | Terminated 21 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio AVT16, Vedolizumab - Ulcerative Colitis | Phase 3 | Terminated | Alvotech Swiss AG | 301 | 2024-09-23 | 2025-12-26 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease | Phase 2 / Phase 3 | Terminated | Bristol-Myers Squibb | 5 | 2023-08-22 | 2025-04-22 |
| A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection Guselkumab, Placebo - Crohn's Disease | Phase 3 | Terminated | Janssen Research & Development, LLC | 4 | 2023-02-21 | 2025-04-29 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ozanimod, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Bristol-Myers Squibb | 131 | 2022-12-09 | 2025-03-26 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 22 | 2022-07-26 | 2024-10-04 |
| Efficacy and Safety of Two Doses of HIL-214 in Children HIL-214, Placebo - Gastroenteritis | Phase 2 / Phase 3 | Terminated | HilleVax | 3084 | 2022-04-28 | 2025-07-10 |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Terminated | AstraZeneca | 12 | 2022-01-18 | 2025-07-14 |
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis | Phase 3 | Terminated | InDex Pharmaceuticals | 171 | 2021-11-24 | 2023-12-27 |
| Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease RoadMAB precision dashboard, Infliximab precision dosing - Crohn Disease | Phase 2 / Phase 3 | Terminated | Children's Hospital Medical Center, Cincinnati | 6 | 2021-10-01 | 2026-03-11 |
| A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease Darvadstrocel - Crohn's Disease, Complex Perianal Fistula | Phase 3 | Terminated | Takeda | 7 | 2021-06-30 | 2025-11-13 |
| Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy Valganciclovir - Ulcerative Colitis, Unspecified | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 6 | 2021-04-22 | 2024-04-10 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet - Chemoradiotherapy-Induced Severe Oral Mucositis | Phase 2 / Phase 3 | Terminated | Monopar Therapeutics | 190 | 2021-02-11 | 2023-05-31 |
| Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis Rosuvastatin 10mg - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Universitaire Ziekenhuizen KU Leuven | 177 | 2020-10-22 | 2025-11-25 |
| A Study of Benralizumab in Patients With Eosinophilic Esophagitis Benralizumab, Matching placebo - Eosinophilic Esophagitis | Phase 3 | Terminated | AstraZeneca | 211 | 2020-09-22 | 2023-11-18 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 46 | 2020-07-23 | 2022-11-02 |
| The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 ) vitamin D3 - Crohn Disease | Phase 3 | Terminated | Jantchou Prevost | 55 | 2020-02-07 | 2026-10-21 |
| A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Etrasimod, Placebo - Crohn's Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 379 | 2020-01-06 | 2026-07-01 |
| Open-label Extension Study of Brazikumab in Crohn's Disease Brazikumab Induction Dose, Brazikumab Maintenance Dose - Crohn's Disease, IBD | Phase 3 | Terminated | AstraZeneca | 18 | 2020-01-06 | 2026-04-01 |
| The Role of Secondary Bile Acids in Intestinal Inflammation ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis | Phase 2 / Phase 3 | Terminated | Stanford University | 2 | 2019-08-26 | 2026-03-11 |
| Efficacy & Safety of TD-1473 in Ulcerative Colitis TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 239 | 2019-03-11 | 2022-11-15 |
Showing 20 of 101. Sign in to see all of them.
Crohn Disease (43) · Colitis, Ulcerative (30) · Inflammatory Bowel Diseases (19) · Mucositis (6) · Gastrointestinal Diseases (5) · Proctitis (4) · Colonic Diseases (3) · Diarrhea (3) · Digestive System Diseases (3) · Diverticulitis (3) · Intestinal Diseases (3) · Neoplasms (3) · Ulcer (3) · Colitis (2)
Digestive System Diseases (98) · Gastrointestinal Diseases (96) · Intestinal Diseases (81) · Inflammatory Bowel Diseases (55) · Colitis (30) · Colonic Diseases (30) · Pathological Conditions, Signs and Symptoms (19) · Pathologic Processes (10) · Signs and Symptoms (10) · Mouth Diseases (6) · Signs and Symptoms, Digestive (6) · Stomatognathic Diseases (6) · Esophageal Diseases (5) · Neoplasms (5)
Mesalamine (8) · Infliximab (5) · ontamalimab (5) · ozanimod (5) · Azathioprine (4) · Adalimumab (3) · CCX282-B (3) · Andrographis paniculata extract (2) · Certolizumab Pegol (2) · GED0301 (2) · GLPG0634 (2) · Hyperbaric Oxygenation (2) · Ondansetron (2) · Prednisolone (2) · Valganciclovir (2)
Shire (6) · Celgene (5) · AstraZeneca (4) · Bausch Health Americas, Inc. (3) · Bristol-Myers Squibb (3) · Dr. Falk Pharma GmbH (3) · Genzyme, a Sanofi Company (3) · GlaxoSmithKline (3) · Janssen Research & Development, LLC (3) · Merck Sharp & Dohme LLC (3) · Assistance Publique - Hôpitaux de Paris (2) · Facet Biotech (2) · Ferring Pharmaceuticals (2) · Hoffmann-La Roche (2) · Hutchison Medipharma Limited (2)
United States (63) · France (38) · Germany (36) · Poland (35) · Canada (34) · Spain (32) · Italy (31) · Belgium (30) · Australia (29) · Israel (28) · Hungary (27) · Netherlands (26) · Ukraine (26) · United Kingdom (25) · Slovakia (24)
Guillermo Rossiter, MD (2) · Kathy Bohannon (2) · Lindsey Mathew (2) · Marc E. Rothenberg, MD, PhD (2) · Sandro Ardizzone, MD (2)
PMID 36208720, PMID 38096402, PMID 28543263, PMID 28707787, PMID 28707796, PMID 32445184, PMID 40013523, PMID 15050885, PMID 17985376, PMID 18477354, PMID 20925534, PMID 20947884, PMID 21688345, PMID 22504093, PMID 23071204, PMID 24512909, PMID 26119226, PMID 26670970, PMID 26946343, PMID 27012778, PMID 28497755, PMID 28627732, PMID 31181017, PMID 31850931, PMID 31982148, PMID 33580845, PMID 37806372, PMID 38924732, PMID 39575597, PMID 39777591, PMID 39954913, PMID 42782131
2017 (6), 2009 (4), 2018 (3), 2019 (3), 2014 (2), 2016 (2), 2023 (2), 2008 (1), 2015 (1), UL1RR024150 (1)